Minimal Residual Disease (MRD) Status Following Induction Chemo-Immunotherapy Predicts Progression-Free Survival In Mantle Cell Lymphoma (MCL): CALGB 50403 (Alliance)Invivoscribe Marketing2021-02-12T00:14:15-08:00August 9th, 2017|2017 Publications, Publications| Read more
Invivoscribe® Releases LeukoStrat® CDx FLT3 Mutation Assay as CE-marked IVD Assay Kit.wmm2021-02-26T19:12:46-08:00August 1st, 2017|2017 Press Releases, Press Releases| Read more